Abstract
Melanoma is the most aggressive and lethal form of skin cancer, characterized by high metastatic potential and increasing incidence worldwide. Recent advances in genomic research have highlighted the significant roles of long non-coding RNAs (lncRNAs) in various malignancies. In this study, we investigate the role of Small nucleolar RNA host gene 5 (SNHG5) in melanoma progression. Our results demonstrate that SNHG5 is significantly upregulated in melanoma tissues and cell lines, and its high expression correlates with advanced clinical stages and poor patient prognosis. Functional studies show that SNHG5 knockdown inhibits cell proliferation and promotes apoptosis in vitro and suppresses tumor growth in vivo. Mechanistically, SNHG5 acts as a molecular sponge for miR-155, thereby modulating its tumor-suppressive functions. These findings suggest that the SNHG5/miR-155 axis is a critical regulator of melanoma development and represents a potential therapeutic target.
Introduction
Melanoma arises from the malignant transformation of melanocytes and is responsible for the majority of skin cancer-related deaths. Despite the development of targeted therapies and immunotherapies, the prognosis for patients with advanced melanoma remains poor due to primary or acquired resistance. Consequently, identifying novel molecular drivers and therapeutic targets is of paramount importance.
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that lack significant protein-coding potential. They function as master regulators of gene expression at transcriptional, post-transcriptional, and epigenetic levels. SNHG5, a member of the small nucleolar RNA host gene family, has been reported to act as an oncogene in several cancers, including gastric and colorectal cancer. However, its specific role and underlying molecular mechanisms in melanoma have not been fully elucidated. This study aims to characterize the expression and function of SNHG5 in melanoma and explore its interaction with microRNAs.
Methods
Clinical Samples and Cell Culture
A total of 22 pairs of melanoma tissues and adjacent normal skin tissues were collected from patients. Five melanoma cell lines (HBL, A375, SK-MEL-2, CHL-1, and VMM917) and a control line of Normal Human Epidermal Melanocytes (NHEM) were utilized for in vitro analysis.
Expression Analysis
Quantitative real-time PCR (RT-qPCR) was employed to detect the expression levels of SNHG5 and miR-155 in both tissues and cell lines.
Functional Assays
To assess the biological impact of SNHG5, loss-of-function experiments were performed using small interfering RNAs (siRNAs) to knock down SNHG5 expression in A375 and SK-MEL-2 cells. Cell proliferation was assessed using MTT and colony formation assays. Apoptosis rates were determined by flow cytometry using Annexin V-FITC and propidium iodide (PI) double staining.
Mechanistic Studies
The subcellular localization of SNHG5 was determined by fractionating the cytoplasm and nucleus. Potential microRNA targets were predicted using the miRcode database. The physical interaction between SNHG5 and miR-155 was validated using dual-luciferase reporter assays and RNA immunoprecipitation (RIP) assays targeting the Ago2 protein.
In Vivo Xenograft Model
To verify the in vitro findings, a mouse xenograft model was established. Melanoma cells with stable SNHG5 knockdown were injected into nude mice, and tumor volume and weight were monitored over time. Additionally, the effect of miR-155 mimics on tumor growth was evaluated in this model.
Results
SNHG5 is Upregulated in Melanoma and Correlates with Poor Prognosis
RT-qPCR analysis revealed that SNHG5 expression was significantly elevated in melanoma tissues compared to normal skin. High SNHG5 levels were positively correlated with advanced TNM stages (III and IV) and were associated with significantly shorter overall survival in patients. Similarly, SNHG5 was found to be 3- to 5-fold more abundant in melanoma cell lines than in normal melanocytes.
SNHG5 Knockdown Inhibits Proliferation and Induces Apoptosis
Silencing SNHG5 in A375 and SK-MEL-2 cells led to a significant reduction in cell viability and a decrease in colony-forming capacity by more than 50%. Furthermore, SNHG5 depletion triggered a substantial increase in programmed cell death, with apoptosis rates rising from a baseline of ~4% to approximately 18-22% in knockdown cells.
SNHG5 Functions as a Molecular Sponge for miR-155
Subcellular fractionation showed that SNHG5 is primarily located in the cytoplasm, suggesting it may function as a competing endogenous RNA (ceRNA). Bioinformatics analysis identified a conserved binding site for miR-155 within SNHG5. Luciferase reporter assays confirmed that miR-155 directly binds to SNHG5. Furthermore, RIP assays demonstrated that both SNHG5 and miR-155 were enriched in Ago2-containing complexes, confirming their physical association.
Restoration of miR-155 Rescues SNHG5-Mediated Effects
To confirm that SNHG5 exerts its oncogenic effects through miR-155, restoration experiments were performed. The inhibition of cell proliferation and induction of apoptosis caused by SNHG5 knockdown were partially reversed when miR-155 was simultaneously inhibited. This indicates that the SNHG5/miR-155 axis is a primary driver of the observed phenotypes.
In Vivo Validation
In the xenograft model, tumors in the SNHG5 knockdown group grew significantly slower and reached smaller volumes and weights compared to control tumors. Injecting a miR-155 mimic into these tumors further enhanced the anti-tumor effect, confirming the oncogenic role of SNHG5 and the tumor-suppressive role of miR-155 in vivo.
Discussion
This study identifies SNHG5 as a key oncogenic lncRNA in melanoma. By sponging miR-155, SNHG5 promotes cell survival and proliferation. The correlation between SNHG5 expression and clinical outcomes underscores its potential utility in patient stratification and prognosis.
While this study clearly defines the SNHG5/miR-155 interaction, it does not identify the downstream messenger RNAs (mRNAs) that miR-155 normally regulates. MicroRNAs usually work by silencing specific proteins; knowing which proteins are "released" when SNHG5 sponges miR-155 would provide a more complete picture of the signaling pathway. Additionally, the clinical sample size (n=22) is relatively small, and larger cohorts would be needed to validate SNHG5 as a robust clinical biomarker.
Conclusion
In summary, SNHG5 is upregulated in melanoma and promotes tumor progression by sponging miR-155. These findings highlight SNHG5 as a potential prognostic biomarker and a promising therapeutic target for the treatment of melanoma.
Summary updated